Mark Lappe insider trades
Open-market stock purchases and sales by Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, Inc, from SEC Form 4 filings since Dec 28, 2020.
Track record: 60% of 10 scored buys are up 5% or more since purchase, averaging +1%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $8.6K |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $208K |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $210K |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $8.6K |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $206K |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $208K |
| Sep 28, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $148K |
| Sep 28, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $305K |
| Sep 25, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $329K |
| Sep 25, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $217K |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $585K |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $665K |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $118K |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $54.1K |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $136K |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc | Bought | $1.1M |